Bristol-Myers’ Opdivo Vs. Merck’s Keytruda In Front-Line Lung Treatment

Merck & Co., Inc. MRK 1% shares are pushing higher by 1.9 percent on Monday following the company’s encouraging new data on Keytruda. On Sunday, Merck reported that Keytruda reduced patient deaths by 40 percent compared to chemotherapy alone and cut disease progression in half.

While that data is great news for Merck shareholders, it’s a blow to competitor Bristol-Myers Squibb Co BMY 0.86%, which is down 8.7 percent in early Monday trading. Bristol-Myers released the full data on disappointing cancer drug Opdivo over the weekend, and the results were even worse than investors had feared. Opdivo has yet to demonstrate that it can slow tumor growth or save lives better than current chemotherapy methods.

Barclays analyst Geoff Meacham sees a clear winner between the two drugs. According to Meacham, Merck could be looking at a potential Keytruda market of up to 60 percent of eligible IL lung patients.

“We see…

Click here to continue reading

Want to learn more about how to profit off the stock market? Or maybe you just want to be able to look sophisticated in front of your coworkers when they ask you what you are reading on your Kindle, and you’d prefer to tell them “Oh, I’m just reading a book about stock market analysis,” rather than the usual “Oh, I’m just looking at pics of my ex-girlfriend on Facebook.” For these reasons and more, check out my book, Beating Wall Street with Common SenseI don’t have a degree in finance; I have a degree in neuroscience. You don’t have to predict what stocks will do if you can predict what traders will do and be one step ahead of them. I made a 400% return in the stock market over five years using only basic principles of psychology and common sense. Beating Wall Street with Common Sense is now available on Amazon, and tradingcommonsense.com is always available on your local internet!